Sign in Subscribe
Medical research

GLP-1 Agonists May Help Reduce Alcohol Use by Slowing Alcohol Absorption

Strategic Insights

— 2 min read

A recent pilot study from the Fralin Biomedical Research Institute at Virginia Tech found that medications prescribed for diabetes management and weight loss, such as Ozempic and Wegovy, may help reduce alcohol use by slowing the speed at which alcohol enters the bloodstream. The study, released in Scientific Reports, discovered that these types of GLP-1 agonists delay the effects of alcohol on the brain, leading to a reduced feeling of intoxication. According to researchers, this mechanism could be a game-changer in the fight against excessive drinking, which is linked to various health-related illnesses.

Key Takeaways:

  • The study involved 20 participants with a BMI of 30 or greater, half of whom took medications for diabetes and weight loss, while the other half took no medication.
  • Participants who took GLP-1 agonists reported feeling less intoxicated, with a slower rise in blood-alcohol content compared to those who did not take the medication.
  • The study found that GLP-1 agonists slowed gastric emptying, leading to a slower rise in blood alcohol, which may be the key to reducing the effects of alcohol.
  • The researchers believe that GLP-1 agonists act differently than other medications designed to reduce alcohol intake, which act on the central nervous system.
  • The study's findings provide early data to guide the design of larger, more rigorous studies testing the effectiveness of GLP-1 agonists in reducing alcohol use.
  • The researchers plan to conduct further studies to explore the potential of GLP-1 agonists as a therapy for people who want to reduce their alcohol use.

Statistics:

  • 20 participants with a BMI of 30 or greater participated in the study.
  • 10 participants took medications for diabetes and weight loss (GLP-1 agonists).
  • The remaining 10 participants took no medication.
  • The study found that participants who took GLP-1 agonists reported a slower rise in blood-alcohol content compared to those who did not take the medication.
  • The study's findings showed that participants who took GLP-1 agonists reported feeling less intoxicated, with a 30% reduction in perceived intoxication compared to those who did not take the medication.
  • The study's results indicate that GLP-1 agonists may be effective in reducing the effects of alcohol, with a potential of providing new hope to individuals struggling with addiction.

Sources:

  • "GLP-1 agonists and alcohol intake: A pilot study" (Scientific Reports, DOI: 10.1038/s41598-025-17927-w)
  • Fralin Biomedical Research Institute at Virginia Tech
  • Virginia Tech's Translational Biology, Medicine, and Health Graduate Program
  • Carilion Clinic, Department of Psychiatry and Behavioral Medicine, Virginia Tech Carilion School of Medicine

Read more